Diagnosis and treatment of ‘insulinoma’

  • Stefan S. Fajans
  • Aaron I. Vinik
Part of the Cancer Treatment and Research book series (CTAR, volume 20)


Insulin-secreting pancreatic islet cell tumors and other forms of organic hyperinsulinism causing fasting and postprandial hypoglycemia are not common disorders that afflict a large portion of any physician’s practice. The fact of the matter is that they are rare disorders. However, endocrinologists continue to see patients by referral in whom the proper diagnosis had been delayed because of a mistaken diagnosis of functional hypoglycemia or other disorders followed by inappropriate therapy for years. The advent of more precise definitions of pancreatic islet cell physiology and of expanded techniques for the study in man, have facilitated a more dependable, simpler and sometimes earlier diagnosis of ‘insulinoma’ and other forms of organic hyperinsulinism. Further, advances have been made in the pre-operative localization of insulin-producing islet cell tumors and in the preoperative differentiation of islet cell tumors from other forms of organic hyperinsulinism. In this contribution we will omit a discussion of the spontaneous hypoglycemias which occur in infancy and childhood.


Insulin Secretion Islet Cell Gastric Inhibitory Polypeptide Islet Cell Tumor Portal Venous System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jaspan JB, Wollman RL, Bernstein L, Rubenstein AH: Hypoglycemic peripheral neuropathy in association with insulinoma: Implication of glucopenia rather than hyperinsulinism. Medicine 61: 33–44, 1982.PubMedGoogle Scholar
  2. 2.
    Cahill GF, et al.: Hormone-fuel interrelationships during fasting. J. Clin Invest 45: 1751–1766, 1966.PubMedGoogle Scholar
  3. 3.
    Cahill GF: Starvation in man. N Engl J Med 282: 668–675, 1970.PubMedGoogle Scholar
  4. 4.
    Exton JH: Gluconeogenesis. Metabolism 21: 945–989, 1972.PubMedGoogle Scholar
  5. 5.
    Madison L: Role of insulin in the hepatic handling of glucose. Arch Intern Med 123: 284–292, 1969.PubMedGoogle Scholar
  6. 6.
    Rizza RA, Mandarino L, Gerich JE: Dose-reponse characteristics for the effects of insulin on production and utilization of glucose in man. Am J Physiol 240: 630–639, 1981B.Google Scholar
  7. 7.
    Rizza RA, Haymond MW, Verdonk CA, Mandarino LJ, Miles JM, Service FJ, Gerich JE: Pathogenesis of hypoglycemia in insulinoma patients. Diabetes 30: 377–381, 1981.PubMedGoogle Scholar
  8. 8.
    Chiasson JL, et al.: Differential sensitivity of glycogenosis and gluconeogenesis in insulin infusion in dogs. Diabetes 25: 283–291, 1976.PubMedGoogle Scholar
  9. 9.
    Chiasson JL, et al.: Effects of insulin at two dose levels on gluconeogenesis from alanine in fasting man. Metabolism 29: 810–818, 1980.PubMedGoogle Scholar
  10. 10.
    Zierler KL, Rabinowitz D: Roles of insulin and growth hormone, based on studies of forearm metabolism in man. Medicine 42: 385–402, 1963PubMedGoogle Scholar
  11. 11.
    Roth J et al.: Receptors for insulin, NSILA-S and growth hormone: Application to disease states in man. Recent Prog Horm Res 31: 95–139, 1976.Google Scholar
  12. 12.
    Bradshaw R, Niall H: Insulin-related growth factors. Trends in Biological Science 3: 274–278, 1978.Google Scholar
  13. 13.
    Megyesi K, et al.: Hypoglycemia in association with extrapancreatic tumors: Demonstration of elevated plasma NSILAS by a new radioreceptor assay. J Clin Endocrinol Metab 38: 931–934, 1974.PubMedGoogle Scholar
  14. 14.
    Daughaday WH, Trivedi B, Kapadia M: Measurement of insulin-like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor-associated hypoglycemia. J Clin Endocrinol Metab 53: 289–294, 1981.PubMedGoogle Scholar
  15. 15.
    Gorden P, Hendricks CM, Kahn CR, Megyesi K, Roth J: Hypoglycemia associated with nonislet-cell tumor and insulin-like growth factors. New Engl J Med 305: 1452–1455, 1981.PubMedGoogle Scholar
  16. 16.
    Kahn CR: Membrane receptors for hormones and neutrotransmitters. J Cell Biol 70: 261–286, 1976.PubMedGoogle Scholar
  17. 17.
    Kahn CR, et al.: Effects of autoantibodies to the insulin receptor on isolated adipocyte. Studies of insulin binding and insulin action. J Clin Invest 60: 1094–1106, 1977.PubMedGoogle Scholar
  18. 18.
    Kahn CR, Rosenthal AS: Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 2: 283–295, 1979.PubMedGoogle Scholar
  19. 19.
    Kahn CR, Baird KL, Flier JS, et al.: Insulin receptors, receptor antibodies, and the mechanism of insulin action. Recent Prog Horm Res 37: 477–538, 1981.PubMedGoogle Scholar
  20. 20.
    Czech MP: Molecular basis of insulin action. Ann Rev Biochem 46: 359–384, 1977.PubMedGoogle Scholar
  21. 21.
    DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–223, 1979.PubMedGoogle Scholar
  22. 22.
    Gavin JR III, Roth J, Neville DM Jr, DeMeyts P, Buess DN: Insulin-dependent regulation of insulin receptor concentrations: A direct demonstration in cell culture. Proc Natl Acad Sci USA 71: 84–88, 1974.PubMedGoogle Scholar
  23. 23.
    Bar RS, Gorden P, Roth J, Kahn CR, DeMeyts P: Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: Effects of starvation, refeeding, and dieting. J Clin Invest 58: 1123–1135, 1976.PubMedGoogle Scholar
  24. 24.
    Insel JR, Kolteran OG, Saekow M, Olefsky JM: Short-term regulation of insulin receptor affinity in man. Diabetes 29: 132–139, 1980.PubMedGoogle Scholar
  25. 25.
    Bar RS, Gorden P, Roth J, Kahn CR, DeMeyts P: Fluctuatons in the affinity and concentration of insuln receptors on circulating monocytes of obese patients: Effects of starvation, refeeding, and deting. J Clin Invest 58: 1123–1125, 1976.PubMedGoogle Scholar
  26. 26.
    Bar RS, Harrison LC, Muggeo M, Gorden P, Kahn CR, Roth J: Regulation of insulin receptor in normal and abnormal physiology in humans. Adv Intern Med 24: 23–52, 1979.PubMedGoogle Scholar
  27. 27.
    Bar RS, Gorden P, Roth J, Siebert CW: Insulin receptors in patients with insulinomas: Changes in receptor affinity and concentration. J Clin Endocrinol Metab 44: 1210–1213, 1977.PubMedGoogle Scholar
  28. 28.
    Insel JR, Kolterman OG, Saekow M, Olefsky JM: Short-term regulation of insulin receptor affinity in man. Diabetes 29: 132–139, 1980.PubMedGoogle Scholar
  29. 29.
    Rizza RA, Gerich JE: Persistent effect of hyperglucagonemia on glucose production in man. J Clin Endocrinol Metab 48: 352–353, 1979.PubMedGoogle Scholar
  30. 30.
    Cherrington AD, Liljenquist JE, Shulman GI, Williams PE, Lacy WW: Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am J Physiol 236: E263–271, 1979.PubMedGoogle Scholar
  31. 31.
    Gerich J, Cryer P, Rizza R: Hormonal mechanisms in acute glucose counterregulation: The relative roles of glucagon, epinephrine, norepinephrine, growth hormone, and Cortisol. Metabolism 29: 1164–1175, 1980.PubMedGoogle Scholar
  32. 32.
    Cryer PE: Hypoglycemic glucose counterregulation in patients with insulin-dependent diabetes mellitus. J Lab Clin Med 99: 451–456, 1982.PubMedGoogle Scholar
  33. 33.
    Sacca L, Morrone G, Cicala M, Corso G, Ungaro B: Influence of epinephrine, norepinephrine, and isoproterenol on glucose homeostasis in normal man. J Clin Endocrinol Metab 50: 680–684, 1980.PubMedGoogle Scholar
  34. 34.
    Sacca L, Vigorito C, Cicala M, Ungaro B, Sherwin RS: Mechanisms of epinephrine-induced glucose intolerance in normal humans. J Clin Invest 69: 284–293, 1982.PubMedGoogle Scholar
  35. 35.
    Rizza RA, Cryer PE, Haymond MW, Gerich JE: Adrenergic mechanisms for the effect of epinephrine on glucose production and clearance in man. J Clin Invest 65: 682–689, 1980.PubMedGoogle Scholar
  36. 36.
    Adamson U, Wahren J, Cerasi E: Influence of growth hormone on splanchnic glucose production in man. Acta Endocrinol 86: 803–812, 1977.PubMedGoogle Scholar
  37. 37.
    MacGorman LR, Rizza RA, Gerich JE: Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab 53: 556–559, 1981.PubMedGoogle Scholar
  38. 38.
    Shamoon H, Hendler R, Sherwin RS: Synergistic interactions among anti-insulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 52: 1235–1241, 1981.PubMedGoogle Scholar
  39. 39.
    Lautt W: Hepatic nerves: A review of the functions and effects. Can J Physiol Pharmacol 58: 105–123, 1980.PubMedGoogle Scholar
  40. 40.
    Nobin ABF, Ingemansson S, Jarhult J, Rosengren E: Organization and function of the sympathetic innervation of the human liver. Acta Physiol Scan 452: 103–106, 1977.Google Scholar
  41. 41.
    Hers HG: The control of glycogen metabolism in the liver. Ann Rev Biochem 45: 167–189, 1976.PubMedGoogle Scholar
  42. 42.
    Sacca L, Hendler R, Sherwin RS: Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones. J Clin Endocrinol Metab 47: 1160–1163, 1979.Google Scholar
  43. 43.
    Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliari AS, Kipnis DM: The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest 58: 7–15, 1976.PubMedGoogle Scholar
  44. 44.
    Cryer PE: Glucose counterregulation in man. Diabetes 30: 261–264, 1981.PubMedGoogle Scholar
  45. 45.
    Clarke WL, Santiago JV, Thomas L, Haymond MW, Ben-Galim E, Cryer PE: Adrenergic mechanisms in recovery from hypoglycemia in man: Adrenergic blockage. Amer J Physiol 236: E147–152, 1979.PubMedGoogle Scholar
  46. 46.
    Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon N, Karam J, Lewis S, Kaplan S, Schultz T, Cryer PE: Hormonal mechanisms of recovery from insulin induced hypoglycemia in man. Amer J Physiol 236: E380–385, 1979.PubMedGoogle Scholar
  47. 47.
    Rizza RA, Cryer PE, Gerich JE: Role of glucagon, epinephrine and growth hormone in human glucose counterregulation: Effects of somatostatin and adrenergic blockade on plasma glucose recovery and glucose flux rates following insulin induced hypoglycemia. J Clin Invest 64: 62–71, 1979.PubMedGoogle Scholar
  48. 48.
    Popp DA, Shah SD, Cryer PE: The role of epinephrine mediated-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin dependent diabetes mellitus. J Clin Invest 69: 315–326, 1982.PubMedGoogle Scholar
  49. 49.
    Voorhees ML, Jakubowski AF, MacGillivary MH: The adrenomedullary and glucagon responses of hypopituitary children to insulin induced hypoglycemia. Pediatr Res 15: 912–915, 1981.Google Scholar
  50. 50.
    Marks V, Greenwood FC, Howorth PJN, Samols E: Plasma growth hormone levels in spontaneous hypoglycemia. J Clin Endocrinol 27: 523, 1967.Google Scholar
  51. 51.
    Cloutier MG, Pek S, Crowther RL, Floyd JC Jr, Fajans SS: Glucagon-insulin interactions in patients with insulin-producing pancreatic islet lesions. J Clin Endocrinol Metab 48: 201–206, 1979.PubMedGoogle Scholar
  52. 52.
    Pruett EDR: Plasma insulin concentrations during prolonged work at near maximal oxygen uptake. J Appl Physiol 29: 155–158, 1970PubMedGoogle Scholar
  53. 53.
    DeFronzo RA, Ferrannini E, Sato Y, Feiig P, Wahren J: Synergistic interaction between exercise and insulin on peripheral glucose metabolism. J Clin Invest 68: 1468–1474, 1981.PubMedGoogle Scholar
  54. 54.
    Feiig P, Wahren J, Hendler R, et al.: Plasma glucagon levels in exercising man. N Engl J Med 287: 184–185, 1972.Google Scholar
  55. 55.
    Galbo H, Holst J, Christensen NJ: Glucagon and plasma catecholamine responses to graded and prolonged exercise in man. J Appl Physiol 38: 70–76, 1975.PubMedGoogle Scholar
  56. 56.
    Vranic M, Berger M: Exercise and diabetes mellitus. Diabetes 28: 147–163, 1979.PubMedGoogle Scholar
  57. 57.
    Christensen NJ, Alberti KGMM, Brandsborg O: Plasma catecholamines and blood substrate concentrations. Eur J Clin Invest 5: 415–423, 1975.PubMedGoogle Scholar
  58. 58.
    Few JD: Effect of exercise in the secretion and metabolism of Cortisol in man. J Endocrinol 62: 341–353, 1974.PubMedGoogle Scholar
  59. 59.
    Schwartz F. Ter Haar DJ, Van Riet HG, Thijssen JHH: Response of growth hormone (GH), FFA, blood sugar and insulin to exercise in obese patients and normal subjects. Metabolism 18: 1013–1020, 1969.Google Scholar
  60. 60.
    Wahren J, Jorfeldt L: Determination of leg blood flow during exercise in man: An indicator dilution technique based on femoral venous dye infusion. Clin Sci 45: 135–145, 1973.Google Scholar
  61. 61.
    Holloszy JO, Narahara HT: Enhanced permeability to sugar associated with muscle contraction. Studies on the role of Ca+ +. J Gen Physiol 50: 551–562, 1967.PubMedGoogle Scholar
  62. 62.
    Vranic M, Wrenshall GA: Exercise, insulin and glucose turnover in dogs. Endocrinology 85: 165–171, 1969.PubMedGoogle Scholar
  63. 63.
    Wahren J, Felig P, Hagnefeldt L: Physical exercise and fuel homeostasis in diabetes mellitus. Diabetologia 14: 213–222, 1978.PubMedGoogle Scholar
  64. 64.
    Porte D Jr, Bagdade JD: Human insulin secretion: An integrated approach. Ann Rev Med 21: 219–240, 1970.PubMedGoogle Scholar
  65. 65.
    Gerich JE, Charles MA, Grodsky GM: Regulation of pancreatic insulin and glucagon secretion. Ann Rev Physiol 38: 353–388, 1976.Google Scholar
  66. 66.
    Hedeskov CJ: Mechanism of glucose-induced insulin secretion. Physiol Rev 60: 442–509, 1980.PubMedGoogle Scholar
  67. 67.
    Both JL, Vinik AI, Blake KCH, Jackson WPU: Kinetics of insulin secretion in chronic pancreatitis and mild maturity-onset diabetes (Evidence for ‘gut hormone’ action beyond glucoreceptor and cyclic adenosine monophosphate mediated insulin release). Europ J Clin Invest 6: 365–372, 1976.Google Scholar
  68. 68.
    Hicks BH, Taylor CI, Vij SK, Pek S, Knopf RF, Floyd JC Jr, Fajans SS: Effect of changes in plasma levels of free fatty acids on plasma glucagon, insulin, and growth hormone in man. Metabolism 26: 1011–1023, 1977.PubMedGoogle Scholar
  69. 69.
    Floyd JC Jr, Fajans SS, Conn JW, Knopf RF, Rull J: Stimulation of insulin secretion by amino acids. J Clin Invest 45: 1487–1502, 1966.PubMedGoogle Scholar
  70. 70.
    Fajans SS, Floyd JC Jr, Knopf RF, Conn JW: Effect of amino acids and proteins on insulin secretion in man. Rec Prog Hormone Res 23: 617–662, 1967.Google Scholar
  71. 71.
    Fajans SS, Floyd JC Jr, Knopf RF, Pek S, Weissman PN, Conn JW: Amino acids and insulin release in vivo. Israel J Med Sci 8: 233–243, 1972.PubMedGoogle Scholar
  72. 72.
    Fajans SS, Knopf RF, Floyd JC Jr, Power L, Conn JW: The experimental induction in man of sensitivity to leucine-hypoglycemia. J Clin Invest 42: 216–229, 1963.PubMedGoogle Scholar
  73. 73.
    Floyd JC Jr, Fajans SS, Knopf RF, Conn JW: Evidence that insulin release is the mechanism for experimentally-induced leucine hypoglycemia in man. J Clin Invest 42: 1714–1719, 1963.PubMedGoogle Scholar
  74. 74.
    Fajans SS: Leucine-induced hypoglycemia. New Engl J Med 272: 1224–1227, 1965.PubMedGoogle Scholar
  75. 75.
    Fajans SS, Floyd JC Jr, Knopf RF, Guntsche E, Rull J, Thiffault CA, Conn JW: A difference in mechanism by which leucine and other amino acids induce insulin release. J Clin Endocrinol Metab 27: 1600–1606, 1967.PubMedGoogle Scholar
  76. 76.
    Floyd JC Jr, Fajans SS, Knopf RF, Conn JW: Plasma insulin in organic hyperinsulinism: Comparative effects of tolbutamide, leucine and glucose. J Clin Endocrinol 24: 747, 1964.Google Scholar
  77. 77.
    Fajans SS, Floyd JC Jr, Vij SK: Differential diagnosis of spontaneous hypoglycemia. In: Endocrinology & Diabetes, Kryston LJ and Shaw RA (eds). Grune & Stratton, Inc, 1975, pp 453–472.Google Scholar
  78. 78.
    Fajans SS, Quibrera R, Pek S, Floyd JC Jr, Christensen HN, Conn JW: Stimulation of insulin release in the dog by a non-metabolizable amino acid. Comparison with leucine and arginine. J Clin Endocrinol Metab 33: 35–41, 1971.PubMedGoogle Scholar
  79. 79.
    Fajans SS, Christensen HN Floyd JC Jr, Pek S: Stimulation of insulin and glucagon release in the dog by a nonmetabolizable arginine analog. Endocrinology 94: 230–233, 1974.PubMedGoogle Scholar
  80. 80.
    Floyd JC Jr, Fajans SS, Pek S, Thiffault CA, Knopf RF, Conn JW: Synergistic effects of essential amino acids and glucose upon insulin secretion in man. Diabetes 19: 109–115, 1970.PubMedGoogle Scholar
  81. 81.
    Dupre J, Curtis JD, Unger RH, et al.: Effects of secretin, pancreozymine or gastrin in the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest 68: 765–767, 1969.Google Scholar
  82. 82.
    Lerner RL, Porte D Jr,: Studies of secretin-stimulated insulin responses in man. J Clin Invest 51: 2205–2210, 1972.PubMedGoogle Scholar
  83. 83.
    Jensen SL, Fahrenkrug J, Hoist JJ, et al.: Secretory effects of VIP on isolated perfused porcine pancreas. Am J Physiol 235: E387–391, 1978.PubMedGoogle Scholar
  84. 84.
    Dupre J, Ross SA, Watson D, Brown J, et al.: Stimulation of insulin secretion by gastic inhibitory polypeptide in man. J Clin Endocrinol Metab 37: 826–828, 1973.PubMedGoogle Scholar
  85. 85.
    Botha JL, Vinik AI, Brown JC: Gastric inhibitory polypeptide (GIP) in chronic pancreatitis. J Clin Endocrinol Metab 2: 791–797, 1976.Google Scholar
  86. 86.
    Vinik A: Gastrointestinal hormones and nutrient balance. Am J Physiol, in press 1984.Google Scholar
  87. 87.
    Unger RH: Insulin-glucagon relationships in the defence against hypoglycemia. Diabetes 32: 575–583, 1983.PubMedGoogle Scholar
  88. 88.
    Samols E, Marri G, Marks V: Promotion of insulin secretion by glucagon. Lancet 2: 415–416, 1965.PubMedGoogle Scholar
  89. 89.
    Samols E, Tyler JM, Marks V: Glucagon-insulin interrelationships. In: Glucagon: Molecular Physiology, Clinical and Therapeutic Implications, Lefebre PJ and Unger RH (eds). Oxford: Pergamon Press, 1972, pp 151–173.Google Scholar
  90. 90.
    Samols E, Weir GC: Adrenergic modulation of pancreatic A, B, and D cells, α-adrenergic suppression and α-adrenergic stimulation of somatostatin secretion, α-adrenergic stimulation of glucagon secretion in the perfused dog pancreas. J Clin Invest 63: 230–238, 1979.PubMedGoogle Scholar
  91. 91.
    Bonner-Weir S, Orci L: New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 31: 883–889, 1982.PubMedGoogle Scholar
  92. 92.
    Koerker DJ, Ruch W, Chideckel E, Palmer J, Goodner CJ, Ensinck J, Gale CC: Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184: 482–484, 1974.PubMedGoogle Scholar
  93. 93.
    Unger RH, Orci L: Possible roles of the pancreatic D-cell in the normal and diabetic states. Diabetes 32: 575–583, 1983.PubMedGoogle Scholar
  94. 94.
    Unger RH, Dobbs RE, Orci L: Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Ann Rev Physiol 40: 307–343, 1978.Google Scholar
  95. 95.
    Robertson RP: Prostaglandins, glucosehomeostatis, and diabetes mellitus. In: Annual Review of Medicine 1983, Creger WP, Coggins CH and Hancock EW (eds). Palo Alto, CA: Annual Review Inc., 1983, pp 1–21.Google Scholar
  96. 96.
    Kajinuma H, Kaneto A, Kuzuya T, et al.: Effects of methacholine on insulin secretion in man. J. Clin Invest 28: 1384–1388, 1968.Google Scholar
  97. 97.
    Halter JB, Porte Jr: Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin. J Clin Endocrinol Metab 46: 952–960, 1978.PubMedGoogle Scholar
  98. 98.
    Robertson RP, Halter JB, Porte D Jr: A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 57: 791–795, 1976.PubMedGoogle Scholar
  99. 99.
    Ipp E, Dobbs RE, Arimura A, et al.: Release of immunoreactive somatostatin from the pancres in response to glucose, amino acids, pancreozymin-cholecystokin, and tolbutamide. J Clin Invest 60: 760–765, 1977.PubMedGoogle Scholar
  100. 100.
    Marco J, Calle C, Roman D, et al.: Hyperglucagonism induced by glucocorticoid treatment in man. N Engl J Med 288: 128–131, 1973.PubMedGoogle Scholar
  101. 101.
    Wise JK, Hendler R, Feiig P: Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 52: 2774–2782, 1973.PubMedGoogle Scholar
  102. 102.
    Berger M, Bordi C, Cuppers H-J, Berchtold P, Gries FA, Müntefering H, Sailer R, Zimmerman H, Orci L: Functional and morphological characterization of human insulinomas. Diabetes 32: 921–931, 1983.PubMedGoogle Scholar
  103. 103.
    Creutzfeldt W, Arnold R, Creutzfeldt C, et al.: Biochemical and morphological investigations of 30 insulinomas. Diabetologia 9: 217–231,1973.PubMedGoogle Scholar
  104. 104.
    Creutzfeldt W: Endocrine tumors of the pancreas. In: The Diabetic Pancreas, Volk BW and Wellman KF, (eds). New York: Plenum Press, 1977, pp 551–590.Google Scholar
  105. 105.
    Harrison TS, Child CG, Fry WJ, Floyd JC Jr, Fajans SS: Current surgical management of functioning islet cell tumors of the pancreas. Ann Surg 178: 485–495, 1973.PubMedGoogle Scholar
  106. 106.
    Harrison TS, Fajans SS, Floyd JC Jr, Thompson NW, Rasbach DA, Santen RJ, Cohen C: Prevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism - problems in recognition and management. World J Surg, in press.Google Scholar
  107. 107.
    Heitz PU, Klöppel G, Häcki WH, Polak JM, Pearse AGE: Nesidioblastosis: The pathologic basis of persistent hyperinsulinemic hypoglycemia in infants: Morphologic and quantitative analysis of seven cases based on specific immunostaining and electron microscopy. Diabetes 26: 632–642, 1977.PubMedGoogle Scholar
  108. 108.
    Harness JK, Geelhoed GW, Thompson NW, Nishiyama RH, Fajans SS, Kraft RO, Howard DR, Clark KA: Nesidioblastosis in adults. A surgical dilemma. Arch Surg 116: 575–580, 1981.PubMedGoogle Scholar
  109. 109.
    Nathan DM, Axelrod L Proppe KH, Wald R, Hirsch HJ, Martin DB: Nesidioblastosis associated with insulin-mediated hypoglycemia in an adult. Diabetes Care 4: 383–388, 1981.PubMedGoogle Scholar
  110. 110.
    Stefanini P, Carboni M, Patrassi N, Basoli A: Beta-islet cell tumors of the pancreas: Results of a study on 1,067 cases. Surg 75: 597–609, 1974.Google Scholar
  111. 111.
    Stefanini P, Carboni M, Patrassi N, Basoli A: Hypoglycemia and insular hyperplasia: Review of 148 cases. Ann Surg 180: 130–135, 1974.PubMedGoogle Scholar
  112. 112.
    Case record of the Masachusetts General Hospital, weekly clinicopathological exercises: Case 1–1983. N Engl J Med 308: 30–37, 1983.Google Scholar
  113. 113.
    Case records of the Massachusetts General Hospital, weekly clinicopathological exercises: Case 30. N Engl J Med 299: 241, 1978.Google Scholar
  114. 114.
    Jaffe R, Hashida Y, Yunis EJ: Pancreatic pathology in hyperinsulinemic hypoglycemia of infancy. Lab Invest 42: 356–365, 1980.PubMedGoogle Scholar
  115. 115.
    Vance JE, Stoll RW, Kitabchi AE, Williams RH, Wood FC Jr: Nesidioblastosis in familial endocrine adenomatosis. JAMA 207: 1679–1682, 1969.PubMedGoogle Scholar
  116. 116.
    Kahn CR: The riddle of tumour hypoglycemia revisited. Clin Endo Metab 9: 335–360, 1980.Google Scholar
  117. 117.
    Vinik AI, Pooler W: Carbohydrate metabolism in patients with primary hepatocellular carcinoma. Clin Sci Mol Med 45: 387–396, 1973.PubMedGoogle Scholar
  118. 118.
    Hyodo T, Megyesi K, Kahn CR, McLean JP, Friesen HG: Adrenocortical carcinoma and hypoglycemia: Evidence of production of nonsuppressible insulin-like activity by the tumor. J Clin Endocrinol Metab 44: 1175–1184, 1977.PubMedGoogle Scholar
  119. 119.
    Zapf J, Walter H, Froesch ER: Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 68: 1321–1330, 1981.PubMedGoogle Scholar
  120. 120.
    Froesch ER, Zapf J, Widmer U: Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. Letter to the Editor. N Engl J Med 306: 1178, 1982.PubMedGoogle Scholar
  121. 121.
    Nouel O, Bernuau J, Rueff B, Benhamou J-P: Hypoglycemia. A common complication of septicema in cirrhosis. Arch Int Med 141: 1477–1478, 1981.Google Scholar
  122. 122.
    Rutsky EA, McDaniel HG, Tharpe DL, Aired G, Pek S: Spontaneous hypoglycemia in chronic renal failure. Arch Int Med 138: 1364–1368, 1978.Google Scholar
  123. 123.
    Garber AJ, Bier DM, Cryer PE, et al.: Hypoglycemia in compensated chronic renal insufficiency: Substrate limitation of gluconeogenesis. Diabetes 23: 982–986, 1974.PubMedGoogle Scholar
  124. 124.
    Dusheiko G, Kew MC, Joffe BI, Lewin JR, Path FF, Mantagos S, Tanaka K: Recurrent hypoglycemia associated with glutaric aciduria type II in an adult. N Engl J Med 301: 1405–1409, 1979.PubMedGoogle Scholar
  125. 125.
    Bleicher SJ: Hypoglycemia. In: Diabetes Mellitus: Theory and Practise, Ellenberg M and Rifkin H (eds). New York: McGraw-Hill Book Co, 1970, pp 958–989.Google Scholar
  126. 126.
    Elias AN, Grant G: Glucose-resistant hypoglycemia in inanition. Arch Int Med 142: 743–746, 1982.Google Scholar
  127. 127.
    Hirata Y, Ishizu H, Ouchi N, et al.: Insulin autoimmunity in a case with spontaneous hypoglycemia. J Jap Diab Soc 13: 312, 1970.Google Scholar
  128. 128.
    Foiling I, Norman N: Hyperglycemia, hypoglycemia attacks and production of anti-insulin antibodies without previous know immunization: Immunological and functional studies in a patient. Diabetes 21: 814, 1972.Google Scholar
  129. 129.
    Onedha A, Matsuda K, Sato M, Yamagata S, Sato T: Hypoglycemia due to apparent autoantibodies to insulin-characterization of inlusin-binding protein. Diabetes 23: 41, 1974.Google Scholar
  130. 130.
    Hirata Y, Tominaga M, Ito J, Noguchi A: Spontaneous hypoglycemia with insulin autoimmunity in Grave’s disease. Ann Int Med 81: 214, 1974.PubMedGoogle Scholar
  131. 131.
    Hirata Y: Spontaneous insulin antibodies and hypoglycemia. In: International Congress Series #413. Amsterdam: Exerpta Medica, 1976, pp 278–284.Google Scholar
  132. 132.
    Ichihara K Shima K, Saito Y, Nonaka K, Tarui S, Nishikawa M: Mechanism of hypoglycemia observed in a patient with insulin autoimmune syndrome. Diabetes 26: 500–506, 1977.PubMedGoogle Scholar
  133. 133.
    Hirata Y, Methimazole and Insulin Autoimmune Syndrome with Hypoglycaemia. Lancet II: 1037, 1983.Google Scholar
  134. 134.
    Goldman J, Baldwin D, Rubenstein AH, Klink DD, Blackard WG, Fisher LK, Roe TF, Schnure JL: Characterization of circulating insulin and proinsulin-binding antibodies in autoimmune hypoglycemia. J Clin Invest 63: 1050–1059, 1979.PubMedGoogle Scholar
  135. 135.
    Anderson JH Jr, Blackard WG, Goldman J, Rubenstein AH: Diabetes and hypoglyceemia due to insulin antibodies. Am J Med 64: 868–873, 1978.PubMedGoogle Scholar
  136. 136.
    Flier JS, Bar RS, Muggeo M, Kahn CR, Roth J, Gorden P: The evolving clinical course of patients with insulin receptor antibodies: Spontaneous remission or receptor proliferation with hypoglycemia. J Clin Endocrinol Metab 47: 985–995, 1978.PubMedGoogle Scholar
  137. 137.
    Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P: Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 307: 1422–1426, 1982.PubMedGoogle Scholar
  138. 138.
    Rosetti L, DePirro R, Lala A, et al.: Severe hypoglycemia associated with insulin receptor autoantibodies. Diabetologia 23: 303, 1982.Google Scholar
  139. 139.
    Freinkel N, Singer DL, Arky RA, et al.: Alcohol hypoglycemia. I. Carbohydrate metabolism of patients with clinical alcohol hypoglycemia and the experimental production of the syndrome with pure alcohol. J Clin Invest 42: 1112–1133, 1963.PubMedGoogle Scholar
  140. 140.
    Jordan RM, Krammer H, Riddle MR: Sulfonylurea-induced factitious hypoglycemia. Arch Int Med 137: 390–393, 1977.Google Scholar
  141. 141.
    Rubenstein AH, Kuzuya H, Horwitz DL: Clinical significance of circulating C-peptide in diabetes mellitus and hypoglycemic disorders. Arch Inter Med 137: 625–632, 1977.Google Scholar
  142. 142.
    Couropmitree C, Freinkel N, Nagel TC, et al.: Plasma C-peptide and diagnosis of factitious hyperinsulinism: Study of an insulin-dependent diabetic patient with ‘spontaneous’ hypoglycemia. Ann Int Med 82: 201–204, 1975.PubMedGoogle Scholar
  143. 143.
    Scarlett JA, Mako ME, Rubenstein AH, et al.: Factitious hypoglycemia: Diagnosis by measurement of C-peptide immunoreactivity and insulin-binding antibodies. N Engl J Med 297: 1029–1032, 1977.PubMedGoogle Scholar
  144. 144.
    Tanaka K, Kean EA, Johnson B: Jamaican vomiting sickness: Biochemical investigation of two cases. N Engl J Med 295: 461–467, 1976.PubMedGoogle Scholar
  145. 145.
    Seltzer HS: Drug-induced hypoglycemia: A review based on 473 cases. Diabetes 21: 955–966, 1972.PubMedGoogle Scholar
  146. 146.
    Quevedo SF, Krauss DS, Chazan JA, Crisafulli FS, Kahn CB: Fasting hypoglycemia secondary to disopyramide therapy. JAMA 245: 2424, 1981.PubMedGoogle Scholar
  147. 147.
    Goldberg I, Brown L, Rayfield E: Disopyramide (Norpace)-induced hypoglycemia. Am J Med 69: 463–466, 1980.PubMedGoogle Scholar
  148. 148.
    Arem R, Garber A, Field JB: Sulfanomide-induced hypoglycemia in chronic renal failure. Arch Int Med 143: 827–829, 1983.Google Scholar
  149. 149.
    Bouchard PH, Sai P, Reach G, Caubarrere I, Ganeval D, Assan R: Diabetes mellitus following pentamide-induced hypoglycemia in humans. Diabetes 31: 40–45, 1982.PubMedGoogle Scholar
  150. 150.
    Sharpe SM: Pentamidine and hypoglycemia. Letter to the Editor. Ann Int Med 99: 128, 1983.PubMedGoogle Scholar
  151. 151.
    Arena FP, Dugowson C, Saudek CD: Salicylate-induced hypoglycemia and ketoacidosis in a nondiabetic adult. Arch Int Med 138: 1153–1154, 1978.Google Scholar
  152. 152.
    Setzer HS, Fajans SS, Conn JW: Spontaneous hypoglycemia as an early manifestation of diabetes mellitus. Diabetes 5: 437–442, 1956.Google Scholar
  153. 153.
    Lev-Ran A: Nadirs of oral glucose tolerance tests are independent of age and sex. Diabetes Care 6: 405–408, 1983.PubMedGoogle Scholar
  154. 154.
    Permutt MA: Postprandial hypoglycemia. Diabetes 25: 719–733, 1976.PubMedGoogle Scholar
  155. 155.
    Cryer PE: Physiology and pathophysiology of the human sympathoadrena neuroendocrine system N Engl J Med 303: 436–444, 1980.PubMedGoogle Scholar
  156. 156.
    Billington CJ, Casciato DA, Choquette DL, Morley JE: Artifactual hypoglycemia associated with polycythemia vera. JAMA 249: 774–775, 1983.PubMedGoogle Scholar
  157. 157.
    Merimee TJ, Tyson JE: Stabilization of plasma glucose during fasting. Normal varations in two separate studies. N Engl J Med 291: 1275–1278, 1974.PubMedGoogle Scholar
  158. 158.
    Fajans SS, Floyd JC Jr,: Fasting hypoglycemia in adults. N Engl J Med 294: 766–772, 1976.PubMedGoogle Scholar
  159. 159.
    Haymond MW, Karl IE, Clarke WL, Pagliara AS, Santiago JV: Differences in circulating gluconeogenic substrates during short-term fasting in men, women, and children. Metabolism 31: 33–42, 1982.PubMedGoogle Scholar
  160. 160.
    Service FJ, Dale AJD, Elveback LR, Jiang N-S: Insulinoma. Clinical diagnostic features of 60 consecutive cases. Mayo Clin Proc 51: 417–429, 1976.PubMedGoogle Scholar
  161. 161.
    Felig P, Lynch V: Starvation in human pregnancy: Hypoglycemia, hypoinsulinemia and hyper- ketonemia. Science 170: 990–992, 1970.PubMedGoogle Scholar
  162. 162.
    Fajans SS, Floyd JC Jr,: Diagnosis and medical management of insulinomas. Ann Rev Med 30: 313–329, 1979.PubMedGoogle Scholar
  163. 163.
    Merimee TJ, Tyson JE: Hypoglycemia in man. Pathologic and physiological varients. Diabetes 26: 161–165, 1977.PubMedGoogle Scholar
  164. 164.
    Turner RC, Oakley NW, Nabarro JDN: Control of basal insulin secretion, with special reference to the diagnosis of insulinomas. Br Med J 2: 132–135, 1971.PubMedGoogle Scholar
  165. 165.
    Sherman BM, Pek S, Fajans SS, Floyd JC Jr, Conn JW: Plasma proinsulin in patients with functioning pancreatic islet cell tumors. J Clin Endocrinol Metab 35: 271–280, 1972.PubMedGoogle Scholar
  166. 166.
    Alsever RN, Roberts JP, Gerber JG, Mako ME, Rubenstein AH: Insulinoma with low circulating insulin levels: The diagnostic value of proinsulin measurements. Ann Int Med 82: 347–350, 1975.PubMedGoogle Scholar
  167. 167.
    Sandler R, Horwitz DL, Rubenstein AH, Kuzuya H: Hypoglycemia and endogenous hyperinsulinism complicating diabetes mellitus. Application of the C-peptide assay to diagnosis and therapy. Am J Med 59: 730–736,1975.PubMedGoogle Scholar
  168. 168.
    Service FJ, Horwitz DL, Rubenstein AH, et al.: C-peptide suppression test for insulinoma. J Lab Clin Med 90: 180–186, 1977.PubMedGoogle Scholar
  169. 169.
    Turner RC, Heding LG: Plasma proinsulin, C-peptide and insulin in diagnostic suppression tests for insulinomas. Diabetologia 13: 571–577, 1977.PubMedGoogle Scholar
  170. 170.
    Fajans SS, Schneider JM, Schteingart DE, Conn JW: The diagnostic value of sodium tolbutamide in hypoglycemic states. J Clin Endocrinol Metab 21: 371–386, 1961.PubMedGoogle Scholar
  171. 171.
    Roy BK, Abuid J, Wendorff H, Nitiyanant W, De Rubertis FR, Field JB: Insulin release in response to calcium in the diagnosis of insulinoma. Metabolism 28: 246–252, 1979.PubMedGoogle Scholar
  172. 172.
    Kaplan EL, Rubenstein AH, Evans R, Lee CH, Klementschitsch P: Calcium infusion: A new provocative test for insulinomas. Ann Surg 190: 501–507, 1979.PubMedGoogle Scholar
  173. 173.
    Harrison TS, Santen RJ: Calcium stimulation test in the evaluation of insulin-secreting pancrea- tic islet-cell tumors. Case report. Milit Med 146: 103–105, 1981.Google Scholar
  174. 174.
    Pointel JP, Villaume C, Gay G, Drouin P, Debry G: Absence of effect of calcium perfusion on blood sugar and plasma insulin in a patient with a benign insulinoma. Horm Metab Res 10: 572–573, 1978.PubMedGoogle Scholar
  175. 175.
    Kakita K, Horino M, Tenku A, Matsumura S, Matsuki M, Nishida S: Absence of insulin release in response to calcium in a patient with a benign insulinoma. Horm Metab Res 13: 237–238, 1981.PubMedGoogle Scholar
  176. 176.
    De Palo C, Sicolo N, Vettor R, Federspil G: Lack of effect of calcium infusion on blood glucose and plasma insulin levels in patients with insulinoma. J Clin Endocrinol Metab 52: 804–806, 1981.PubMedGoogle Scholar
  177. 177.
    Miller JL, Klaff LB, Abrahamson MJ, Marine N: Failure of calcium infusion as a provocative test for insulinoma. N Engl J Med 304: 1430, 1981.PubMedGoogle Scholar
  178. 178.
    Hayashi M, Floyd JC Jr, Pek S, Fajans SS: Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism. J Clin Endocrinol Metab 44: 681–694, 1977.PubMedGoogle Scholar
  179. 179.
    Floyd JC Jr, Fajans SS, Pek S, Chance RE: A newly regognized pancreatic polypeptide: Plasma levels in health and disease. Rec Prog Horm Res 33: 519–570, 1977.Google Scholar
  180. 180.
    Glaser B, Valtysson G, Vinik AI, Fajans SS, Cho K, Thomson NW: Gastrointestinal/pancreatic hormone concentrations in the portal venous system of nine patients with organic hyperinsulinism. Metabolism 30: 1001–1010, 1981.PubMedGoogle Scholar
  181. 181.
    Kahn CR, Rosen SW, Weintraub BD, Fajans SS, Gorden P: Ectopic production of chorionic gonadotropin and its subunits by islet-cell tumors. A specific marker for malignancy. N Engl J Med 297: 565–569, 1977.PubMedGoogle Scholar
  182. 182.
    Louis LH, Fajans SS, Conn JW, Struck WA, Wright JB, Johnson JL: The structure of a urinary excretion product of l-Butyl-3-p-tolysulfonylurea (Orinase). J Am Chem Soc 78: 5701–5702, 1956.Google Scholar
  183. 183.
    Bauman WA, Yalow RS: Differential diagnoses between endogenous and exogenous insulin- induced refractory hypoglycemia in a nondiabetic patient. N Engl J Med 303: 198–199, 1980.PubMedGoogle Scholar
  184. 184.
    Arky RA, Freinkel N: Alcohol infusion to test gluconeogenesis in starvation, with special reference to obesity. N Engl J Med 274: 426, 1966.PubMedGoogle Scholar
  185. 185.
    LeQuesne LP, Nabarro JDN, Kurtz A, Zweig S: The management of insulin tumours of the pancreas. Br J Surg 66: 373–378, 1979.Google Scholar
  186. 186.
    Dagget PR, Goodburn EA, Kurtz AB, LeQuesne LP, Morris DV, Nabarro JDN, Raphael MJ: Is preoperative localisation of insulinomas necessary? Lancet 1: 484–486, 1981.Google Scholar
  187. 187.
    Turner RC, Morris PJ, Lee ECG, Harris EA: Localization of insulinomas. Lancet 1: 515–518, 1978.PubMedGoogle Scholar
  188. 188.
    Miller DR: Functioning adenomas of pancreas with hyperinsulinism. Arch Surg 90: 509–520, 1965.PubMedGoogle Scholar
  189. 189.
    Olsson O: Angiographic diagnosis of an islet cell tumor of the pancreas. Acta Chir Scand 126: 346, 1963.PubMedGoogle Scholar
  190. 190.
    Robins JM, Bookstein JJ, Oberman HA, Fajans SS: Selective aangiography in localizing isletcell tumors of the pancreas. A further appraisal. Radiology 106: 525–528, 1973.PubMedGoogle Scholar
  191. 191.
    Clouse ME, Costello P, Legg MA: Sub-selective angiography in localizing insulinomas of the pancreas. Am J Roentg 128: 741, 1977.Google Scholar
  192. 192.
    Gray BK, Rosch J, Grollman JH: Arteriography in the diagnosis of islet-cell tumors. Radiology 97: 39–44, 1970.PubMedGoogle Scholar
  193. 193.
    Fulton RE, Sheedy PF, Mclllrath DC, Ferris DO: Preoperative angiographic localization of insulin producing tumors of the pancreas. Am J Roent 123: 367–377, 1975.Google Scholar
  194. 194.
    Edis AJ, Mclllrath DC, Van Heerden JA, Fulton RE, Sheedy PF, Service FJ, Dale AJ: Insulinoma-current diagnosis annd surgical management. Curr Probl Surg 13. 3–45, 1976.Google Scholar
  195. 195.
    Dunnick NR, Long JA Jr, Krudy A, Shawker TH, Doppman JL: Localizing insulinomas with combined radiographic methods. Am J Roent 135: 747–752, 1980.Google Scholar
  196. 196.
    Alfidi RJ, Bhyun DS, Crile G Jr, Hawk W: Arteriography and hypoglycemia. Surg Gynec Obstet 133: 477–452, 1971.Google Scholar
  197. 197.
    Lunderquist A, Tylen U: Phlebography of the pancreatic veins. Radiologie 15: 198–202, 1975.Google Scholar
  198. 198.
    Stefanini P, Carboni M, Petrassi N, DeBernardinis G, Negro P, Blandamura V: The value of arteriography in the diagnosis and treatment of insulinomas. Am J Surg 131: 352–356,1976.PubMedGoogle Scholar
  199. 199.
    Korobkin MT, Palubinskas AJ, Glickman MG: Pitfalls in arteriography of islet-cell tumors of the pancreas. Radiology 100: 319–328, 1971.PubMedGoogle Scholar
  200. 200.
    Dunnick NR, Doppman JL, Mills SR, McCarthy DM: Computed tomographic detection of non-beta pancreatic islet cell tumors. Radiology 135: 117–120, 1980.PubMedGoogle Scholar
  201. 201.
    Ingemansson S, Lunderquist A, Lundquist I, Loudahl R, Tibbin S: Portal and pancreatic vein catheterization with radioimmunologic determination of insulin. Surg Synec Obstet 141: 705–711, 1975.Google Scholar
  202. 202.
    Ingemansson S, Kühl C, Larsson L-I, Lunderquist A, Lunderquist I: Localization of insulinomas and islet cell hyperplasia by pancreatic vein catheterization and insulin assay. Surg Gynecol Obstet 146: 725–734,1978.Google Scholar
  203. 203.
    Dunn E, Stein S: Percuteous transhepatic pancreatic vein catheterization in localization of insulinoma. Arch Surg 116: 232–233, 1981.PubMedGoogle Scholar
  204. 204.
    Cho KJ, Vinik AI, Thompson NW, Shields JJ, Porter DJ, Brady TM, Cadavid G, Fajans SS: Localization of the source of hyperinsulinism: Percutaneous transhepatic portal and pancreatic vein catheterization with hormone assay. Am J Roentg 139: 237–245,1982.Google Scholar
  205. 205.
    Vinik AI, Strodel WE, Cho KJ, Eckhauser FE, Thompson NW: Localization of hormonally active gastrointestinal tumors. In: Endocrine Surgery Update, Thompson N, Vinik A (eds). New York: Grune and Stratton, 1983, pp 195–218.Google Scholar
  206. 206.
    Vinik AI, Strodel WE, Lloyd RV, Thompson NW: Unusual gastroenteropancreatic (GEP) tumors and their hormones. In: Endocrine Surgery Update, Thompson N, Vinik A (eds). New York: Grune and Stratton, 1983, pp 293–320.Google Scholar
  207. 207.
    Reichardt W, Cameron R: Anatomy of the pancreatic veins. A post morten and clinical Phlebographic investigation. Acta Radiolo 21: 33–41, 1980.Google Scholar
  208. 208.
    Doppman JL, Brennan MF, Dunnick NR, Kahn CR, Gorden P: The role of pancreatic venous sampling in the localization of occult insulinomas. Radiology 138: 557–562, 1981.PubMedGoogle Scholar
  209. 209.
    Fajans SS, Floyd JC Jr, Knopf RF, Rull J, Guntsche EM, Conn JW: Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man. J Clin Invest 45: 481, 1966.PubMedGoogle Scholar
  210. 210.
    Fajans SS, Floyd JC Jr, Thiffault CA, Knopf RF, Harrison TS, Conn JW: Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man. Ann NY Acad Sci 150: 261–280, 1968.PubMedGoogle Scholar
  211. 211.
    Neri V, Bartorelli A, Faglia G: Effect of propanolol on the blood sugar, immunoreactive blood insulin in a patient with insulinoma. Acta Diabetol Lat 6: 809–819, 1969.PubMedGoogle Scholar
  212. 212.
    Blum I, Doron M, Laron Z, et al.: Prevention of hypoglycemic attacks by propranolol in a patient suffering from insulinoma. Diabetes 24: 535–537, 1975.PubMedGoogle Scholar
  213. 213.
    Shaklai M, Aderka D, Blum I, et al.: Suppression of hypoglycemia attacks and insulin release by propranolol in a patient with metastatic malignant insulinoma. Diabete Metab 3: 155–158, 1977.PubMedGoogle Scholar
  214. 214.
    Hofeldt FD, Dippe SE, Levin SR, Karam JH, Blum MR, Forsham PH: Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes 23: 192, 1973.Google Scholar
  215. 215.
    Brodows RG, Campbell RG: Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. J Clin Endocrinol Metab 38: 159–161, 1974.PubMedGoogle Scholar
  216. 216.
    Federspil G, Casara D, Stauffacher W: Chlorpromazine in the treatment of endogeneous organic hyperinsulinism. Diabetologia 10: 189, 1974.PubMedGoogle Scholar
  217. 217.
    Schein PS: Chemotherapeutic management of the hormone-secreting endocrine malignancies. Cancer 30: 1616–1626, 1972.PubMedGoogle Scholar
  218. 218.
    Broder LE, Carter SK: Chemotherapy of malignant insulinomas with streptozotocin. In: International Congress Series #314, Excerpta Medica,1974, pp 714–727.Google Scholar
  219. 219.
    Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189–1194, 1980.PubMedGoogle Scholar
  220. 220.
    Kiang DT, Frenning DH, Bauer GE: Mithramycin for hypoglycemia in malignant insulinoma. N Engl J Med 299: 134–135, 1978.PubMedGoogle Scholar
  221. 221.
    Eastman RC, Come SE, Strewler GJ, Gorden P, Kahn CR: Adriamycin therapy for advanced insulinoma. J Clin Endocrinol Metab 44: 142–148, 1977.PubMedGoogle Scholar
  222. 222.
    Warne GL, Adie R, Hansky J, Martin FIR, Varigos G: Prolonged control of hypoglycemia by L-asparaginase in islet cell carcinoma producing insulin and gastrin. Aust NZJ Med 5: 466, 1975.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Stefan S. Fajans
  • Aaron I. Vinik

There are no affiliations available

Personalised recommendations